Trials / Completed
CompletedNCT02077777
Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an "in Vivo" Evaluation of the Molecular Effects on β-catenin Signaling Pathway.
Azione Chemiopreventiva Della Mesalazina Sul Cancro Del Colon-retto: Studio Pilota Per la Valutazione Degli Effetti Molecolari "in Vivo" Sulla Via di Segnalazione Proliferativa Della β-catenina (Official Title in Italian Language)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- SOFAR S.p.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to obtain an "in vivo" confirmation that mesalazine induces the gene expression of μ-protocadherin and other related genes in the colon mucosa, as demonstrated in some "in vitro" experiments. .
Detailed description
Pilot Trial, single-blind, parallel group on biopsy specimens of healthy colon mucosa in patients with precancerous lesions of the colon and rectum (adenomas) treated with mesalazine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mesalazine | Mesalazine cpr 800 mg t.i.d. for 3 months |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2016-06-01
- Completion
- 2016-06-01
- First posted
- 2014-03-04
- Last updated
- 2016-12-02
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT02077777. Inclusion in this directory is not an endorsement.